Makale detayı · 2016
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
YÖKSİS
OpenAlex
SJR Q1
JCR Q1
Atıf 558
Üst %1
Yüzdelik 99.4%
FWCI 13.83
- Yıl
- 2016
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Journal of Hepatology
- Katalog eşleşmesi (ISSN) Journal of Hepatology
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
558 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 10 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis 2021
- An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B 2022
- Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 2018
- Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 2018
- Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 2020
- Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B 2021
- Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment 2022
- Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy 2021
- Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B 2021
- Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort 2026